Reduction of thrombosis in canine coronary bypass vein grafts with dipyridamole and aspirin.
The potential benefit of platelet inhibitor drugs in reducing early thrombosis of coronary arterial vein bypass grafts was assessed in dogs. There were 26 control dogs and 24 dogs treated with dipyridamole, 55 mg/day plus aspirin, 325 mg/day. The dogs in both groups were killed at 2 hours and 1, 2, 3, 7 and 14 days after operation. The grafts were perfused with fixative in vivo, harvested and examined with light microscopy. Severe alterations of the graft wall were observed in the dogs in both groups. The grafts in the control group had a high incidence rate of thrombosis, which occurred early after the operation; those in the treated group had a significantly reduced incidence of thrombosis (p = 0.025). Our study indicates that a combined regimen of dipyridamole and aspirin is effective in reducing early graft thrombosis in dogs.
D000818:Animals; D001241:Aspirin / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D004176:Dipyridamole / Q000627:therapeutic use*; D004285:Dogs; D005268:Femoral Vein / Q000637:transplantation; D013927:Thrombosis / Q000188:drug therapy* / Q000473:pathology
D004176:Dipyridamole; D001241:Aspirin